Diagnosis and therapy of cancer (i.e. leukemia and prostate) tailored for the patient subgroup re-sistant to TRAIL induced apopt
TRAIL has recently emerged as a novel potential anticancer agent. However, cancer cells are in specific patients resistant to TRAIL induced apoptosis. Therefore the efficacy of chemotherapy for treatment of CLL, MCL, HNSCC, bladder or prostate carci-noma is often limited due to resistance to TRAIL induced apoptosis. The technology provides a method for identification of these non-responders. Moreover, a polynucleotide encoding the modified TRAIL can serve as drug against such cancer diseases of this specific patient subgroup.
Further Information: PDF
Deutsches Krebsforschungszentrum DKfZ
Phone: +49-6221-422958
Contact
Regina Otto
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
